|Up date on TAF (Truvada 2.0)
Mar 30, 2016
Hello Dr. Young, I just had my biannual ID clinic visit at the large teaching hospital I attend and I was offered the once a day pill containing TAF. Since I have done so well on Isentress without any side effects, I declined and we discussed where the new Truvada 2.0 was concerning the approval of it. She said that she felt very sure that when I come back in six months it will have been approved and I will be making the switch to the new version. Best to you, Billy
Response from Dr. Young
Hello and thanks for posting.
I agree with you, and would support your decision to stay on the Isentress regimen- while not as sexy as a single pill, the raltegravir+Truvada regimen remains one of the select few on the US government recommended initial treatments, besting Atripla and Complera, who were demoted to "alternate" status last year. Since you've done well on the twice daily Isentress for a while, there's little to suggest that you'll do poorly in the future.
Regarding the new TAF/FTC combination (aka, Truvada 2.0), the tea leaves are pointing towards a FDA approval in the next couple of months.
Hope that's helpful, BY
Did I develop resistance?
Change of regimen
- Muscle Ache After Sex With Hooker Sign Of HIV AIDS
- Tingling Lips After Oral Sex On A Woman What Are The Chances Of HIV
- Can Someone Get Std If They Get Fingered?
- Can You Get Hep C From Kissing A Hep C Infected Person?
- Can Cunnilingus Cause Hiv Transfer?
- Hiv Test At Six Weeks With Third Generation Test
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.